Metraipolis › archive › dc_2df92a7b995f

Discontinuation of the development of remimazolam for ICU sedation in Japan: background and rationale — Europe PMC PMID:41566504

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41566504
DOI
10.1186/s40560-[numero omesso]-8
License (as archived)
solo-consultazione
Archived
2026-11-06T15:36:40.090Z
SHA-256 of the archived text
8622d77cfc0111e164c81222a48f4f7281e6f21a9aabf638bd9c370788c1eff0
Stable URL of this page
https://metraipolis.com/documento/dc_2df92a7b995f

How to cite

Discontinuation of the development of remimazolam for ICU sedation in Japan: background and rationale — Europe PMC PMID:41566504 — Europe PMC (en), https://europepmc.org/article/MED/41566504 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_2df92a7b995f (Metraipolis archive dc_2df92a7b995f, sha256 8622d77cfc0111e164c81222a48f4f7281e6f21a9aabf638bd9c370788c1eff0)
BibTeX
@misc{dc2df92a7b995f,
  title = {Discontinuation of the development of remimazolam for ICU sedation in Japan: background and rationale — Europe PMC PMID:41566504},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41566504},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_2df92a7b995f; sha256 8622d77cfc0111e164c81222a48f4f7281e6f21a9aabf638bd9c370788c1eff0},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41566504. Agents can read the archived copy with the MCP tool read_document.